TPCW
KYMR icon

TD Private Client Wealth’s Kymera Therapeutics KYMR Stock Holding History

TD Private Client Wealth’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.6K Hold
14
– – ﹤0.01% 1397
2026
Q1 		$1.17K Buy
14
+2
+17% +$158 ﹤0.01% 1360
2025
Q4 		$934 Hold
12
– – ﹤0.01% 1379
2025
Q3 		$679 Buy
+12
New +$541 ﹤0.01% 1399

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

TD Private Client Wealth's KYMR Position: Q2 2026 in Review

TD Private Client Wealth held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 14 shares worth $1.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1397.

TD Private Client Wealth first reported a position in KYMR in Q3 2025 and has held it in 4 quarters since. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • TD Private Client Wealth held 14 shares of Kymera Therapeutics worth $1.6K as of Q2 2026.
  • TD Private Client Wealth left its Kymera Therapeutics share count unchanged in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1397 holding.
  • TD Private Client Wealth first reported a position in Kymera Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.